BioMedomics has developed and launched one of the world’s first rapid point-of-care lateral flow immunoassays (antibody test) for the diagnosis of 2019-nCoV novel coronavirus infection, it could be used “for rapid screening of carriers of the virus that are symptomatic or asymptomatic”. As mentioned by Dr James Lyons-Weiler this test has been available since February 2020 seemingly unbeknownst to Dr Fauci.
This lateral flow combined antibody test rapidly detects both early marker and late marker, IgM/IgG antibodies in human finger-prick (capillary) or venous whole blood, serum, and plasma samples. It takes 15 minutes for a result compared to PCR test which are greater than 1 hour in a lab. It can be used for rapid screening of carriers of the virus that are symptomatic or asymptomatic, though on 16 March 2020 the FDA restricted it’s use to lab and hospital settings only – forcing people to exit their home to test!